

10th Annual Hepatitis and Chronic Liver Disease Seminar

|  |  |  |  |
| --- | --- | --- | --- |
| **Conference****Location** | **Costa Mesa, CA – April 26, 2025**

|  |  |
| --- | --- |
| **Hilton Orange County-Costa Mesa**3050 Bristol StreetC Costa Mesa, California 92626  |  **Phone: (714) 540-7000**[https://www.hilton.com/en/hotels/snacmhh-hilton-orange-county-costa-mesa](https://url.avanan.click/v2/___https%3A//www.hilton.com/en/hotels/snacmhh-hilton-orange-county-costa-mesa___.YXAzOndjLWl0Z3JvdXA6YTpvOjdjNjZlZmE5MjU4MTQzYmQ3YTIzNTMwMTkzYjI5ZGUxOjY6NDU3Zjo0YTlmYjUwODVmNzQ5NTJlOWIwODczYWYzZWQxNjU1NGQ1MDJkM2U1MjI5ODc2OTZlNjE0ZTRhNDRhMGE5OWEwOnA6VDpO)  |

 |
| **Parking at the Conference** | Discounted Self-Parking of $10,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rateA special guest room rate is available for a limited time. Please contact us for more information. |
| **Driving Directions** | Follow I-405 N or S to Bristol Street in Costa Mesa. Continue on Bristol Street going West. Just before you reach Paularino Avenue, the hotel is on your left. |
| **Seminar Agenda and Syllabus Information**  | Registration begins at **7:30 a.m.** in the Balboa Room. **The Hepatitis and Chronic Liver Disease seminar is a paperless program**. The **course syllabus and related materials will be made available on a digital app** that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided. Wi-Fi will be available without charge. |
| **Pre-Program Assignments** | **Pre-Lecture 1 - 2025 Viral Hepatitis Update –** A summary for discovery and natural history of viral hepatitis (25mins)**Pre-Lecture 2 - End Stage Liver Disease**: A systematic overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process (45 mins) |
| **7:30 am** | ***Registration and View Exhibits*** |
| **8:00 am** | **Opening Comments and Pre-Test** |
| **8:25 am** | **Hepatitis C-Elimination and Care for Special Populations**  * Recap the highlights of Pre-Lecture 1
* Viral Hepatitis Elimination - Caring for At-risk populations – homeless, PWID, the incarcerated, HIV-infected individuals
* Approved Direct Acting Antivirals
* The vital role of specialty pharmacy
* Clinical Cases and Discussion: HCV and At-Risk Individuals
 |
| **9:05 am** | **Hepatitis B: Epidemiology, Natural History, Testing and Therapies** * Efficacies and opportunities in HBV testing and vaccination.
* Disease progression and impact on liver health
* The efficacy of HBV Vaccination
* Anti-viral therapies of HBV
* HBV Re-activation
* Latest studies from EASL and AASLD
 |
| **9:40 am** | **Delta Hepatitis and Hepatitis E Update** * Global and US perspective on the rapid growth of Delta Hepatitis
* Bulevirtide for Delta Hepatitis
* Testing and surveillance approaches
* Real world outcome studies on HDV and HEV
 |
| **10:15 am** | ***Disease Awareness Session –presented by Alexion/AstraZeneca Rare Diseases – Overview of LAL-D***Break and View Exhibits |
| **11:00 am** | **End Stage Liver Disease: Recap and Clinical Cases** * A review of Pre-course lecture on end-stage liver disease
* Complications of cirrhosis
* Liver transplant in the era of DAA’s
* Clinical cases to illustrate HE. HRS and/or Thrombocytopenia
 |
| **11:30 am** | **Hepatocellular Carcinoma (HCC) - Disease Progression in the US*** Screening diagnostic serum assays and imaging tests
* Treatment and management options: Ablation, TACE and Surgery
* New studies showing cost effectiveness of surveillance post SVR
* PRIUS Study (MRI vs US) Abbreviated MRI
* 2024 AASLD screening guidance for liver cancer. New guidelines are less critical of liver biopsy for cancer detection
 |
| **12:00 pm** | **Hepatocellular Carcinoma: New Systemic Treatment Options** * **A case-based approach to HCC treatment**
* Promising 1st and 2nd line therapies for liver cancer
* New data on the benefit of downstaging
* New chemotherapy regimens in development and Immunotherapy as the new HCC MoA
* Checkpoint inhibitors and VEGE inhibitors
 |
| **12:30 pm** | ***Lunch and Industry Presentation by Ipsen Pharmaceuticals - Unlocking Treatment Possibilities for PBC*** Dessert & View Exhibits |
| **1:15 pm** | **Cholestatic Liver Disease: Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Pruritus** * Predicting outcomes and Improving Survival in PSC patients
* Coping with the clinical features of PBC
* Ursodeoxycholic Acid (UDCA) and Obetacholic Acid
* Highlights of the ELATIVE, RESONSE and ASSURE studies on PBC

Understanding cholestatic pruritus and helping patients cope with the itching |
| **2:10 pm** | **Alcohol Associated Liver Disease** * The growing prevalence of alcohol over-consumption and its impact on liver health
* Alcohol consumption and malnutrition
* Promising therapeutic agents for AAH and other alcohol associated liver disease
 |
| ***2:45 pm*** | * ***Break and Exhibits***
 |
| **3:00 pm** | **Steatotic Liver Disease: The new healthcare epidemic** * New naming conventions for fatty liver disease: MASLD and MASH– what and why?
* Epidemiology, Demographics and Diagnosis
* Scoring, Staging and Management of Metabolic Liver Disease
* The ‘unhealthy” rise in MASLD in the US population and What can be done
 |
| **3:40 pm** | **MASH Treatments in Practice and in Development** * Current therapies for NASH including Updates from AASLD and EASL
* Lifestyle changes as a therapy
* Drugs in clinical development for NASH – Semaglutide and Resmeterom

MASH Diagnosis and Treatment case |
| **4:25 pm** | **Closing Comments, Post-test and Wrap-Up**  |
| **Post Program Lectures:** | **Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome (**30 mins) **Lecture 4 – AASLD Update – Highlights of the 2024 AASLD Liver Meeting (**80 mins) |
| **Attendance Policies** | **Attendee Cancellation, Substitution, Refund**The course tuition is refundable, minus a $20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.” **Recording and Photography** The Colorado Medical Society reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.**Guest Attendance** All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas. **Conference Modification or Cancellation****The Colorado Medical Society and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided.** We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.  |
| **CME Information** | **Physicians (MD/DO**) - The Colorado Medical Society Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 *AMA PRA Category 1 Credit(s)*™.** Physicians should claim only the credit commensurate with the extent of their participation in the activity.**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME. |
| **Your Seminar Faculty** | **TIMOTHY MORGAN, MD, FAASLD**Dr. Timothy Morgan is Chief of Gastroenterology at the VA Long Beach Healthcare System and Professor of Medicine at the University of California, Irvine. Dr. Morgan is the Director of the VA National Hepatitis C Resource Center which oversees programs to improve diagnosis and treatment of hepatitis C, and improve care for patients with cirrhosis, across the VA healthcare system. He is a co-chair of the AASLD-IDSA hepatitis C treatment guideline committee and chair of the VA HCV treatment guidelines. He has been an investigator on clinical trials in hepatitis C for the past 25 years, and in alcoholic hepatitis and alcoholic cirrhosis for the past 30 years. He is currently the Principal Investigator on the Southern California Alcoholic Hepatitis Consortium, to evaluate new treatments and better understand the alcoholic hepatitis. Dr. Morgan is a fellow of the American College of Physicians, American Gastroenterology Association, the American Association for the Study of Liver Disease**A person wearing glasses and a white shirt  Description automatically generated with low confidence****BRIAN LEE, MD**Dr. Lee is an adult hepatologist within the Digestive Health Institute at Hoag Health. He is triple board-certified in internal medicine, gastroenterology, and transplant hepatology. He practices in Newport Beach and Irvine with a focus on patient care in the diagnosis and treatment of complex liver diseases. His clinical interests include liver cancer, autoimmune liver diseases and alloimmune complications after liver transplantation.Dr. Lee earned his medical degree from Rush Medical College at Rush University Medical Center in Chicago, Ill. and completed his residency in internal medicine and fellowship in gastroenterology at the University of Southern California/LAC+USC and another fellowship in transplant hepatology at Icahn School of Medicine at Mount Sinai in New York.Medium shot of a person smiling  Description automatically generated**TAMMY HARPER, NP-C** Tammy Harper received her undergraduate degree at Union University in Tennessee and her Masters Degree in nursing from the University of California in Los Angeles. Tammy Harper joined the UCS Keck Scholl of Medicine team in 2013, after 14 years of practicing internal medicine. Her clinical interest and expertise are in chronic liver disease and liver transplantation. Tammy has participated in research studies related to Hepatitis C infections, including Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved Sustained Virologic Response to Direct Acting Antiviral Agents for Recurrent Infection After Transplant. |